Evaluation and Management of Chronic Inguinal Lymph Node Enlargement

Initial Assessment

The National Comprehensive Cancer Network recommends performing a thorough clinical examination to evaluate palpability, number of inguinal masses, unilateral or bilateral presentation, dimensions, mobility or fixation of nodes, and relationship to other structures 1, 2
30-50% of palpable inguinal lymphadenopathy cases are due to inflammatory lymph node swelling rather than metastatic disease, as stated by the National Comprehensive Cancer Network 3, 1

Fine-needle aspiration cytology (FNA) is the standard initial diagnostic approach for palpable inguinal lymph nodes, with a sensitivity of 91.7% and specificity of 98.2% for detecting malignancy, according to the American Urological Association 4, 5
If FNA is negative but clinical suspicion remains high, consider excisional biopsy for definitive diagnosis, as recommended by the American College of Surgeons 1

For confirmed reactive lymphadenopathy, address underlying cause (infection, inflammation) and follow-up with clinical examination of the affected region, as suggested by the American College of Physicians 1
If FNA is positive for malignancy, proceed with appropriate oncologic management based on the primary malignancy, such as immediate inguinal lymph node dissection (ILND) for penile cancer with positive nodes, as recommended by the American Urological Association 4, 5

For confirmed reactive lymphadenopathy, regular clinical examinations to monitor node size and characteristics are recommended by the American College of Physicians 1
For malignant lymphadenopathy, follow-up according to primary cancer management protocols and consider repeat imaging to assess treatment response, as suggested by the National Comprehensive Cancer Network 3, 8